approval of axi-cel in second-line for r/r lbcl & label update
Published 2 years ago • 52 plays • Length 1:21Download video MP4
Download video MP3
Similar videos
-
2:45
the value of axi-cel as a second-line treatment in r/r lbcl
-
1:34
advances and unmet needs in second-line treatment of dlbcl
-
1:13
second-line treatment strategies for patients with relapsed dlbcl
-
1:43
approval of exa-cel for scd
-
0:59
matching-adjusted indirect comparison of liso-cel vs axi-cel in the 2l treatment of r/r lbcl
-
24:35
how dna origami disrupts medicine and becomes the new cornerstone of nano robotics | dld 23
-
1:46:07
hematology lecture
-
1:00:07
what you need to know about biosecurity ii
-
3:53
standard-of-care setting results of axi-cel in r/r large b-cell lymphoma
-
3:08
welcome to the video journal of hematology & hematological oncology 🎥🩸
-
0:47
novel agents being explored for the treatment of immune-mediated ttp
-
1:25
the use of clonoseq to monitor mrd in patients with lbcl treated with axi-cel in zuma-7
-
1:34
recent and upcoming data on axi-cel for patients with nhl
-
3:33
a novel composite endpoint of toxicity and pfs in patients with r/r fl treated with axi-cel
-
2:52
zuma-24 preliminary analysis of axi-cel in the outpatient setting in patients with r/r lbcl
-
1:32
the importance of cytogenetics and molecular profiling for accurate aml/mds diagnosis
-
2:59
low-intensity venetoclax-based preconditioning followed by sequential allosct for r/r aml or hr-mds
-
1:46
novel quadruplet and triplet front-line options for early r/r multiple myeloma
-
2:41
an overview of the latest advances in hematology
-
1:26
next-generation diagnostic and prognostic approaches in multiple myeloma
-
2:13
haploidentical sct for the treatment of secondary aml
-
2:00
update of a phase i trial investigating lintuzumab-ac225 plus venetoclax in r/r aml